Search results for "GFR"

showing 10 items of 206 documents

PROGNOSTIC VALUE OF ESTIMATED GLOMERULAR FILTRATION RATE IN HOSPITALIZED ELDERLY PATIENTS

2013

A multicenter observational study, REPOSI (REgustri POliterapie Società Italiana di Medicina Interna), was conducted to assess the prognostic value of glomerular filtration rate (eGFR) on in-hospital mortality, hospital readmission and death within 3 months, in a sample of elderly patients (n=1,363) admitted to 66 internal medicine and geriatric wards. Bases on eGFR, calculated by the new Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, subjects at hostpital admission were classified into three groups: group 1 with normal eGFR (60 ml/min/1.73m2, reference group), group 2 with moderately reduced eGFR (30-59 ml/min/1.73 m2) and group 3 with severely reduced eGFR (<30 ml/m…

Settore MED/09 - Medicina InternaMulticenter study in-hospital elderly patients comorbidity polypharmacy eGFR
researchProduct

INVERSE RELATIONSHIP BETWEEN AORTIC ROOT DIAMETER AND RENAL FUNCTION IN HYPERTENSIVE SUBJECTS

2015

Introduction: Dilatation of aortic root is associated with presence and severity of aortic regurgitation and risk for aortic dissection. Recent studies performed in general population suggest that enlarged aortic root diameter (ARD) may predict cardiovascular events in absence of aneurysmatic alterations. Little is known about the influence of renal function on ARD. Aim: To assess the relationships between glomerular filtration rate (GFR) and ARD in hypertensive subjects. Methods: We enrolled 611 hypertensive individuals (mean age: 52 ± 15 years; men 63 %) consecutively attending our outpatient nephrology and hypertension unit. Patients on dialysis treatment, with valvulopathy more than mil…

Settore MED/14 - NefrologiaSettore MED/09 - Medicina Internarenal functionCKDCardiovascular risk.Settore MED/11 - Malattie Dell'Apparato CardiovascolareAORTIC ROOT DIAMETERGFRREANAL FUNCTION.Aorta
researchProduct

Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.

2020

Background &amp; Aims: Limited data on treatment of elderly patients with hepatocellular carcinoma (HCC) increase the unmet need. REACH and REACH-2 were global phase III studies of ramucirumab in patients with HCC after prior sorafenib, where patients with alpha-fetoprotein (AFP) ≥400 ng/mL showed an overall ssurvival (OS) benefit for ramucirumab. These post-hoc analyses examined efficacy and safety of ramucirumab in patients with HCC and baseline AFP ≥ 400 ng/mL by three prespecified age subgroups (&lt;65, ≥65 to &lt;75 and ≥75 years). Methods: Individual patient data were pooled from REACH (baseline AFP ≥400 ng/mL) and REACH-2. Kaplan-Meier and Cox proportional hazards regression methods …

Sorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinoma[SDV.CAN]Life Sciences [q-bio]/CancerSorafenib intolerancePlaceboAntibodies Monoclonal HumanizedGastroenterologyRamucirumabRamucirumabCàncer de fetge03 medical and health sciences0302 clinical medicineElderlyInternal medicineCox proportional hazards regressionMedicineHumansAgedHepatologyElevated alpha-fetoproteinbusiness.industryPersones grans dependentsHazard ratioLiver Neoplasms[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyHepatitis CSorafenibmedicine.diseaseFrail elderly3. Good healthVEGFR2Treatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology030211 gastroenterology & hepatologyMonoclonal antibodiesAlpha-fetoprotein (AFP)alpha-FetoproteinsbusinessAnticossos monoclonalsLiver cancermedicine.drugLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution

2021

For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a n…

TIMPsEGFRiRhomsTNFAnti-Inflammatory AgentsPharmaceutical ScienceInflammationContext (language use)Antineoplastic AgentsDiseaseComputational biologyReviewADAM17 ProteinmetalloproteinasesAnalytical Chemistrylcsh:QD241-44103 medical and health sciences0302 clinical medicineImmune systemlcsh:Organic chemistryIn vivoNeoplasmsDrug DiscoverymedicineDisintegrinTIMPADAM17 ProteinAnimalsHumansPhysical and Theoretical Chemistry030304 developmental biologyInflammation0303 health sciencesADAM17biologyOrganic ChemistryIntracellular Signaling Peptides and ProteinsiRhomChemistry (miscellaneous)030220 oncology & carcinogenesisbiology.proteinADAM17; Ectodomain shedding; EGFR; IRhoms; Metalloproteinases; TIMPs; TNF; ADAM17 Protein; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Humans; Inflammation; Intracellular Signaling Peptides and Proteins; NeoplasmsMolecular MedicineTumor necrosis factor alphametalloproteinaseectodomain sheddingmedicine.symptomMolecules
researchProduct

Interactions between cholinergic and fibroblast growth factor receptors in brain trophism and plasticity

2014

Acetylcholine, acting on both nicotinic receptors (nAChRs) and muscarinic receptors (mAChRs), plays a role in the regulation of synaptic plasticity, being involved in the regulation of cellular processes and cognitive functions, such as learning, memory and attention. Recently, G protein coupled receptors (GPCRs), including mAChRs, have been reported to transactivate tyrosine-kinase receptors (RTK), such as epidermal growth factor receptor (EGFR), and initiate their intracellular signaling. In this minireview we have first analysed the RTK transactivation mechanisms, involving cholinergic receptors, and thereafter the interplay between AChR and neurotrophic factor systems built up by FGF2 a…

Transcriptional Activationmedicine.medical_specialtyClass C GPCRG protein coupled receptorBiologyCholinergic AgonistsBiochemistrySynaptic plasticityTransactivationNicotinic receptorNeurotrophic factorsInternal medicinemedicineAnimalsHumansReceptors CholinergicProtein Interaction MapsReceptorMolecular BiologyG protein-coupled receptorTransactivationNeuronal PlasticityFibroblast growth factor receptor 1Muscarinic receptorBrainReceptor Protein-Tyrosine KinasesCell BiologyGeneral MedicineReceptors Fibroblast Growth FactorErbB ReceptorsEndocrinologyFGFR1Fibroblast growth factor receptorFGFR1; G protein coupled receptor; Muscarinic receptors; Nicotinic receptors; Receptor-receptor interaction; Synaptic plasticity; Transactivation; Tyrosine-kinase receptorsSignal transductionTyrosine-kinase receptorsNeuroscienceReceptor-receptor interactionSignal Transduction
researchProduct

Abstract 20: Inhibition of mutant EGFR in NSCLC promotes endothelin-1-mediated NSCLC disease progression and angiogenesis

2018

Abstract Despite recent advances in the treatment of NSCLC targeting of EGFR kinase domain mutations with tyrosine kinase inhibitors (TKIs), work needs to be done to reduce morbidity and improve survival for NSCLC patients. In NSCLC, tumor angiogenesis has been identified as important therapeutic target in combination with EGFR TKIs. However, only small advancements have been made for the use of angiogenesis inhibitors in NSCLC and it remains elusive why the inhibition of VEGF-mediated neovascularization is not therapeutically efficacious. We present evidence that a subpopulation of NSCLC cells with the EGFR TKI-induced epithelial to mesenchymal transition (EMT) contributes to the attenuati…

Tube formationCancer Researchbusiness.industryAngiogenesisCancermedicine.diseaserespiratory tract diseasesNeovascularizationGefitinibOncologymedicineCancer researchEpithelial–mesenchymal transitionmedicine.symptombusinessTyrosine kinaseEGFR inhibitorsmedicine.drugCancer Research
researchProduct

A través del espejo. Mirando el cine con Siegfried Kracauer

2013

La cuestión de la relación entre el cine y las artes conduce a una dialéctica básica, en la que el cine se enfrenta a sí mismo. En esta confrontación se plantea la cuestión sobre el estatuto artístico del cine. Sobre esta dialéctica se establece otra, que la atraviesa. El carácter tanto figurativo como escénico del cine (representacional en el doble sentido de la palabra), conduce a la dualidad revelación y redención. Esta tesis, que fue desarrollada por Siegfried Kracauer, exige una reflexión sobre la ontología del ser social y la lucha por el reconocimiento. Este artículo sintetiza los dos libros sobre el cine de Kracauer y corrige aquellas interpretaciones que lo tildan de realista más o…

UNESCO::CIENCIAS DE LAS ARTES Y LAS LETRASHernàndez i DobonFrancesc Jesús 407 420:CIENCIAS DE LAS ARTES Y LAS LETRAS [UNESCO]AnacletoCinematografia0211-5808 9678 Archivo de arte valenciano 367242 2013 94 4718843 A través del espejo. Mirando el cine con Siegfried Kracauer Ferrer Mas
researchProduct

Akadēmiskā Dzīve, 45.krājums

2008

Zinātniskās pētniecības ekspedīcija ĒģiptēAkadēmiskā vienība "Auseklis"Latviešu valodaRakstībaValodas attīstībaIedzīvotāju izglītotībaJuris UpatnieksVardarbības attēlojumsAkadēmiskā vienība "Austrums"Jānis JaunsudrabiņšAkadēmiskā vienība "Latviete"Informācijas vide LatvijāZviedrijas literatūras vēstureDemokrātijas diskursiLatvijas literatūras vēstureSabiedriskās domas veidošanāsĒģiptoloģija:SOCIAL SCIENCES::Social sciences::Education [Research Subject Categories]Latvijas Republikas vēstureZigfrīds Anna MeierovicsMediju redakcionālā autonomijaBrīvmūrniecībaPārmaiņas valodāStudentu biedrība "Fraternitas Rusticana"Baznīcas medijiLatviešu katoļu studentu un akadēmiķu apvienība "Dzintars"Politiskais mārketingsĀrzemju latviešu ģeozinātņu darbinieki (1945-1990)AizliegumsHologrāfijaAlvis Kučers
researchProduct

Fluorescein- and EGFR-Antibody Conjugated Silica Nanoparticles for Enhancement of Real-time Tumor Border Definition Using Confocal Laser Endomicrosco…

2019

Intraoperative definition of tumor free resection margins in head and neck cancer is challenging. In the current proof-of-principle study we evaluated a novel silica nanoparticle-based agent for its potential use as contrast enhancer. We synthesized silica nanoparticles with an average size of 45 nm and modified these particles with the fluorescence stain fluorescein isocyanate (FITC) for particle detection and with epidermal growth factor receptor (EGFR)-targeting antibodies for enhanced tumor specificity. The nanoparticles exhibited good biocompatibility and could be detected in vitro and in vivo by confocal laser scanning microscopy. Additionally, we show in an ex vivo setting that these…

biologyBiocompatibilityGeneral Chemical EngineeringConfocalEGFRcontrast agentsilica nanoparticlesStainEGFR AntibodyArticlelcsh:Chemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicinechemistrylcsh:QD1-999In vivo030220 oncology & carcinogenesisbiology.proteinGeneral Materials ScienceEpidermal growth factor receptorFluorescein030223 otorhinolaryngologyEx vivoBiomedical engineeringNanomaterials
researchProduct

Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Neg…

2015

BC-11 is an easily synthesized simple thiouronium-substituted phenylboronic acid, which has been shown to be cytotoxic on triple negative MDA-MB231 breast cancer cells by inducing a perturbation of cell cycle when administered at a concentration equal to its ED50 at 72 h (117 μM). Exposure of cells to BC-11, either pre-absorbed with a soluble preparation of the N-terminal fragment of urokinase-plasminogen activator (uPa), or in co-treatment with two different EGFR inhibitors, indicated that: (i) BC-11 acts via binding to the N-terminus of the enzyme where uPa- and EGF receptor-recognizing sites are present, thereby abrogating the growth-sustaining effect resulting from receptor binding

boronic acidPharmaceutical ScienceGene ExpressionApoptosisAnalytical ChemistryDrug DiscoveryCytotoxic T cellSettore BIO/06 - Anatomia Comparata E CitologiaCytotoxicityEGFR inhibitorschemistry.chemical_classificationCell CycleDrug SynergismCell cycleBoronic AcidsMitochondriaErbB ReceptorsBiochemistryChemistry (miscellaneous)Molecular MedicinecytotoxicityFemaleQD0241Antineoplastic AgentsArticlelcsh:QD241-441plasminogen activator inhibitorbreast cancerlcsh:Organic chemistryCell Line TumorHumansPhysical and Theoretical ChemistryMammary Glands HumanCell ProliferationQD0415Reactive oxygen speciesHydrobromideOrganic ChemistryEpithelial CellsBC-11Molecular biologyUrokinase-Type Plasminogen ActivatorPlasminogen InactivatorsEnzymechemistryApoptosisQuinazolinesMDA-MB231 cellsReactive Oxygen Speciesboronic acid; BC-11; plasminogen activator inhibitor; breast cancer; cytotoxicity; MDA-MB231 cellsMolecules
researchProduct